Welcome to our dedicated page for Tango Therapeutics SEC filings (Ticker: TNGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tango Therapeutics, Inc. filings document a clinical-stage precision oncology business and its Nasdaq-listed common stock. Current reports disclose operating and financial results, business highlights for vopimetostat and related development programs, material agreements, capital-raising arrangements such as at-the-market common stock sales, and updates to governance and executive leadership.
Proxy and compensation disclosures cover board matters, executive pay, pay-versus-performance data, equity awards, and shareholder voting matters. The company’s filings also address officer appointments and departures, separation and employment agreements, compensatory arrangements, capital structure, risk factors, and other material events affecting its biotechnology operations.
Tango Therapeutics director John B. Ketchum received an equity grant consisting of 4,000 restricted stock units and an option for 25,000 shares of Common Stock. The RSUs vest in full on the earlier of June 5, 2027 or the next annual stockholder meeting, subject to continued service. The stock option, with a $20.22 exercise price, vests in 12 equal monthly installments beginning July 5, 2026 and expires on June 5, 2036. Following these grants, Ketchum directly holds 24,937 shares of Common Stock.
Tango Therapeutics director John B. Ketchum received an equity grant consisting of 4,000 restricted stock units and an option for 25,000 shares of Common Stock. The RSUs vest in full on the earlier of June 5, 2027 or the next annual stockholder meeting, subject to continued service. The stock option, with a $20.22 exercise price, vests in 12 equal monthly installments beginning July 5, 2026 and expires on June 5, 2036. Following these grants, Ketchum directly holds 24,937 shares of Common Stock.
Tango Therapeutics director Lesley Ann Calhoun received new equity awards, increasing her direct stake in the company. She was granted 4,000 shares of Common Stock in the form of restricted stock units and now directly holds 16,500 Common shares after this award.
She was also granted options to purchase 25,000 shares of Common Stock at an exercise price of $20.2200 per share, expiring on June 5, 2036. The RSUs vest in full on the earlier of June 5, 2027 or the next annual stockholder meeting, while the options vest in 12 equal monthly installments starting July 5, 2026, in each case subject to her continuous service.
Tango Therapeutics director Lesley Ann Calhoun received new equity awards, increasing her direct stake in the company. She was granted 4,000 shares of Common Stock in the form of restricted stock units and now directly holds 16,500 Common shares after this award.
She was also granted options to purchase 25,000 shares of Common Stock at an exercise price of $20.2200 per share, expiring on June 5, 2036. The RSUs vest in full on the earlier of June 5, 2027 or the next annual stockholder meeting, while the options vest in 12 equal monthly installments starting July 5, 2026, in each case subject to her continuous service.
Tango Therapeutics director Mace Rothenberg reported equity awards in the form of restricted stock units and stock options. The filing shows a grant of 4,000 shares of Common Stock represented by restricted stock units, plus a stock option for 25,000 shares at an exercise price of $20.2200 per share.
The restricted stock units vest in full on the earlier of June 5, 2027 or the next annual meeting of stockholders, subject to continuous service. The option vests in 12 substantially equal monthly installments over one year starting on July 5, 2026 and expires on June 5, 2036. After the stock grant, Rothenberg holds 41,500 shares of Common Stock directly.
Tango Therapeutics director Mace Rothenberg reported equity awards in the form of restricted stock units and stock options. The filing shows a grant of 4,000 shares of Common Stock represented by restricted stock units, plus a stock option for 25,000 shares at an exercise price of $20.2200 per share.
The restricted stock units vest in full on the earlier of June 5, 2027 or the next annual meeting of stockholders, subject to continuous service. The option vests in 12 substantially equal monthly installments over one year starting on July 5, 2026 and expires on June 5, 2036. After the stock grant, Rothenberg holds 41,500 shares of Common Stock directly.
Tango Therapeutics director Lee Sung received new equity awards consisting of restricted stock units and stock options. The filing shows a grant of 570 RSUs, each representing one share of common stock, increasing her direct common stock holdings to 22,870 shares after the award.
An additional stock option covering 3,570 shares of common stock was granted with an exercise price of $20.22 per share and an expiration date of June 5, 2036. The RSUs vest in full on the earlier of June 5, 2027 or the next annual stockholder meeting, while the option vests in 12 equal monthly installments starting July 5, 2026, in each case contingent on continued service.
Tango Therapeutics director Lee Sung received new equity awards consisting of restricted stock units and stock options. The filing shows a grant of 570 RSUs, each representing one share of common stock, increasing her direct common stock holdings to 22,870 shares after the award.
An additional stock option covering 3,570 shares of common stock was granted with an exercise price of $20.22 per share and an expiration date of June 5, 2036. The RSUs vest in full on the earlier of June 5, 2027 or the next annual stockholder meeting, while the option vests in 12 equal monthly installments starting July 5, 2026, in each case contingent on continued service.
Tango Therapeutics is offering $500,000,000 of its common stock pursuant to a preliminary prospectus supplement dated June 8, 2026. The offering is made under the company’s shelf registration on Form S-3. The prospectus states 144,162,543 shares outstanding as of March 31, 2026, and that net tangible book value was $391.5M, or $2.72 per share as of that date. The underwriters have a 30-day option to purchase up to an additional $75,000,000 of shares. The prospectus describes intended uses of proceeds for general corporate purposes, R&D, pivotal trial expenses and potential commercialization, and states the company expects proceeds plus existing cash to fund operations into 2030. The offering includes customary underwriting arrangements, a 60-day lock-up for certain insiders, and continued availability of an ATM program with up to $35.6M capacity as of June 5, 2026.
Tango Therapeutics is offering $500,000,000 of its common stock pursuant to a preliminary prospectus supplement dated June 8, 2026. The offering is made under the company’s shelf registration on Form S-3. The prospectus states 144,162,543 shares outstanding as of March 31, 2026, and that net tangible book value was $391.5M, or $2.72 per share as of that date. The underwriters have a 30-day option to purchase up to an additional $75,000,000 of shares. The prospectus describes intended uses of proceeds for general corporate purposes, R&D, pivotal trial expenses and potential commercialization, and states the company expects proceeds plus existing cash to fund operations into 2030. The offering includes customary underwriting arrangements, a 60-day lock-up for certain insiders, and continued availability of an ATM program with up to $35.6M capacity as of June 5, 2026.
Tango Therapeutics reported initial Phase 1/2 data for its PRMT5 inhibitor vopimetostat combined with Revolution Medicines’ RAS(ON) inhibitors in hard‑to‑treat cancers. In previously treated MTAP‑deleted, RAS‑mutant pancreatic cancer, vopimetostat plus daraxonrasib produced a 92% objective response rate in 12 evaluable patients and a 90% six‑month progression‑free survival rate, with all patients achieving disease control.
Three non‑small cell lung cancer patients on the same combination all responded. A separate vopimetostat plus zoldonrasib arm in pancreatic cancer showed a 52% objective response rate and 74% six‑month progression‑free survival in 27 evaluable patients, with 96% disease control. Safety across combinations was generally favorable, with mostly mild or moderate side effects and no treatment‑related grade 4 or 5 events or discontinuations.
Based on these results, Tango plans to advance the vopimetostat plus daraxonrasib regimen into Phase 3 development as a front‑line, chemotherapy‑free option for MTAP‑deleted pancreatic cancer, while exploring second‑line registration paths and broader development of its PRMT5 franchise.
Tango Therapeutics reported initial Phase 1/2 data for its PRMT5 inhibitor vopimetostat combined with Revolution Medicines’ RAS(ON) inhibitors in hard‑to‑treat cancers. In previously treated MTAP‑deleted, RAS‑mutant pancreatic cancer, vopimetostat plus daraxonrasib produced a 92% objective response rate in 12 evaluable patients and a 90% six‑month progression‑free survival rate, with all patients achieving disease control.
Three non‑small cell lung cancer patients on the same combination all responded. A separate vopimetostat plus zoldonrasib arm in pancreatic cancer showed a 52% objective response rate and 74% six‑month progression‑free survival in 27 evaluable patients, with 96% disease control. Safety across combinations was generally favorable, with mostly mild or moderate side effects and no treatment‑related grade 4 or 5 events or discontinuations.
Based on these results, Tango plans to advance the vopimetostat plus daraxonrasib regimen into Phase 3 development as a front‑line, chemotherapy‑free option for MTAP‑deleted pancreatic cancer, while exploring second‑line registration paths and broader development of its PRMT5 franchise.
Tango Therapeutics, Inc. held its 2026 annual stockholder meeting on June 4, 2026 in a virtual-only format. Of 144,242,271 common shares entitled to vote as of April 7, 2026, 131,198,081 shares were present or represented by proxy, representing 90.96% and establishing a quorum.
Stockholders elected Class II directors Malte Peters, M.D. (98,188,796 votes for; 17,623,596 withheld; 15,385,689 broker non-votes) and Mace Rothenberg, M.D. (92,476,172 for; 23,336,220 withheld; 15,385,689 broker non-votes), each to serve until the 2029 annual meeting.
They also ratified PricewaterhouseCoopers, LLP as independent registered public accounting firm for the year ending December 31, 2026 (131,097,992 for; 73,823 against; 26,266 abstain) and approved, on a non-binding advisory basis, compensation of named executive officers (113,915,877 for; 1,855,838 against; 40,677 abstain; 15,385,689 broker non-votes).
Tango Therapeutics, Inc. President of R&D Crystal Adam reported an exercise-and-sale transaction in company stock. On June 1, 2026, she exercised 27,000 stock options at $5.20 per share and sold 27,000 common shares in open-market trades at weighted average prices of $22.25 and $23.06 per share. These trades were executed under a pre-arranged Rule 10b5-1 trading plan. After the transactions, she directly holds 142,743 shares of common stock and 341,040 stock options.
Tango Therapeutics, Inc. amendment reports that TCG Crossover II entities and Chen Yu together beneficially hold 11,597,737 shares of Common Stock, representing 8.1% of the class. The disclosure states this position includes 1,066,666 shares underlying pre-funded warrants exercisable within 60 days.
The filing cites a pool of 143,735,517 shares used for calculation, reflecting 142,668,851 shares outstanding as of February 26, 2026 plus the exercisable pre-funded warrants. It notes a Beneficial Ownership Limitation that caps exercises at 9.99%.
Tango Therapeutics, Inc. Schedule 13G/A reports that Nextech Crossover I SCSp and related reporting persons beneficially own 7,266,081 shares of common stock as of March 31, 2026. The filing states this represents 5.1% of the issuer's outstanding shares, based on 142,688,851 shares outstanding as of February 26, 2026. The cover rows show that Nextech Crossover I SCSp directly holds the shares, Nextech Crossover I GP S.a. r.l. is the general partner, and Ian Charoub, Costas Constantinides and Rocco Sgobbo have the power to direct voting and disposition of those securities. The Reporting Persons expressly disclaim status as a 'group.'